Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without the...

Oculogica Adds to IP Portfolio with Patent for Assessment of Impairment Due to Cannabis NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...

Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...

Oculogica Announces New Category 3 CPT Code Created by American Medical Association NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has...

Oculogica Receives FDA Marketing Authorization for EyeBOX®, the First Non-Invasive, Baseline-Free Test for Concussion NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced that the U.S. Food and Drug Administration (FDA) granted their De Novo request...